Therapeutic Evaluation of Epstein-Barr Virus-encoded Latent Membrane Protein-1 Targeted DNAzyme for Treating of Nasopharyngeal Carcinomas
Authors:
Open Access
- 1 February 2014
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 22 (2) , 371-377
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Down-Regulation of EBV-LMP1 Radio-Sensitizes Nasal Pharyngeal Carcinoma Cells via NF-κB Regulated ATM ExpressionPLOS ONE, 2011
- Down-regulation of BLIMP1α by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomasBlood, 2011
- Intratumoral Epidermal Growth Factor Receptor Antisense DNA Therapy in Head and Neck Cancer: First Human Application and Potential Antitumor MechanismsJournal of Clinical Oncology, 2009
- EBV Latent Membrane Protein 1 Activates Akt, NFκB, and Stat3 in B Cell LymphomasPLOS Pathogens, 2007
- Brothers in ArmsThe American Journal of Pathology, 2007
- Silencing of LMP1 Induces Cell Cycle Arrest and Enhances Chemosensitivity Through Inhibition of AKT Signaling Pathway in EBV-Positive Nasopharyngeal Carcinoma CellsCell Cycle, 2007
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006
- Epstein-Barr Virus Transforming Protein LMP1 Plays a Critical Role in Virus ProductionJournal of Virology, 2005
- Epstein-barr virus latent membrane protein 1: Structure and functionsJournal of Biomedical Science, 2003
- Antiviral agent Cidofovir decreases Epstein–Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignanciesOncogene, 2003